The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases

Minerva Endocrinologica

Volumn 34, Issue 1, 2009, Pages 57-69

  De Klerk, J M H ^a   Oyen, W J G ^b  

^a MEANDER MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Therapy Catheter ablation Iodine; Thyroid neoplasms

Indexed keywords

IODINE 131; LEVOTHYROXINE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; RADIOPHARMACEUTICAL AGENT; RECOMBINANT PROTEIN; THYROTROPIN;

CATHETER ABLATION; DOSIMETRY; HUMAN; LYMPH NODE METASTASIS; METASTASIS; RADIATION DOSE; REVIEW; THYROID CANCER; THYROIDECTOMY; ADJUVANT THERAPY; ADULT; AGED; CARCINOMA; CHEMICALLY INDUCED DISORDER; FEMALE; HYPOTHYROIDISM; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; RADIOMETRY; THYROID TUMOR; TUMOR RECURRENCE;

ADULT; AGED; CARCINOMA; FEMALE; HUMANS; HYPOTHYROIDISM; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN;

EID: 67650348504     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Links TP, Huysmans DA, Smit JW, de Heide LJ, Hamming JF, Kievit J et al. [Guideline "Differentiated thyroid carcinoma", including diagnosis of thyroid nodules]. Ned Tijdschr Geneeskd 2007;151:1777-82.
2. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
3. Verburg FA, de KB, Lips CJ, Zelissen PM, de Klerk JM. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol 2005;152:33-7.
4. Gerrard G, Gill V. Thyroid cancer guidelines - what's new? Clin Oncol (R Coll Radiol) 2008;20:264-6.
5. Pacini F, Castagna MG, Brilli L, Jost L. Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19 Suppl 2:ii99-101.
6. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.
7. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al.; The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.
8. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008;35:1941-59.
9. Van Nostrand D., Wartofsky L. Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin North Am 2007;36:807-viii.
10. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 2005;153:651-9.
11. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab 2007;92:28-38.
12. Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf) 2000;52:765-73.
13. Doi SA, Woodhouse NJ, Thalib L, Onitilo A. Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited. Clin Med Res 2007;5:87-90.
14. de Klerk JM, de KB, Zelissen PM, Lips CM, Koppeschaar HP. Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy. Nucl Med Commun 2000;21:529-32.
15. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-85.
16. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002;87:4063-8.
17. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003;88:4110-5.
18. Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 2002;43:1482-8.
19. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92:3542-6.
20. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91:926-32.
21. Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008;49:764-70.
22. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47:648-54.
23. Borget I, Remy H, Chevalier J, Ricard M, Allyn M, Schlumberger M et al. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging 2008;35:1457-63.
24. Remy H, Borget I, Leboulleux S, Guilabert N, Lavielle F, Garsi J et al. 131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med 2008;49:1445-50.
25. Maxon HR, III, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990;19:685-718.
26. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962;87:171-82.
27. Lassmann M, Hanscheid H, Chiesa C, Hindorf C, Flux G, Luster M. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 2008;35:1405-12.
28. Schober O, Gunter HH, Schwarzrock R, Hundeshagen H. [Long-term hematologic changes caused by radioiodine treatment of thyroid cancer. I. Peripheral blood changes]. Strahlenther Onkol 1987;163:464-74.
29. Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 2002;12:121-34.
30. Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys 1976;3:253-5.
31. Nadig MR, Pant GS, Bal C. Usefulness of 99mTc-pertechnetate single-photon emission computed tomography in remnant mass estimation of postsurgical patients of differentiated thyroid cancer during internal dosimetry. Nucl Med Commun 2008;29:809-14.
32. Pacini F, Cetani F, Miccoli P, Mancusi F, Ceccarelli C, Lippi F et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg 1994;18:600-4. (Pubitemid 24273863)
33. Coburn M, Teates D, Wanebo HJ. Recurrent thyroid cancer. Role of surgery versus radioactive iodine (I131). Ann Surg 1994;219:587-93.
34. Robbins RJ, Schlumberger MJ. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med 2005;46 Suppl 1:28S-37S.
35. Coburn M, Teates D, Wanebo HJ. Recurrent thyroid cancer. Role of surgery versus radioactive iodine (I131). Ann Surg 1994;219:587-93.
36. Verburg FA, de Keizer B, Lam MG, de Klerk JM, Lips CJ, Borel-Rinkes IH et al. Persistent disease in patients with papillary thyroid carcinoma and lymph node metastases after surgery and iodine-131 ablation. World J Surg 2007;31:2309-14.
37. Salvatori M, Rufini V, Reale F, Gajate AM, Maussier ML, Revelli L et al. Radio-guided surgery for lymph node recurrences of differentiated thyroid cancer. World J Surg 2003;27:770-5. (Pubitemid 37022386)
38. Pereira JA, Jimeno J, Miquel J, Iglesias M, Munné A, Sancho JI et al. Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery 2005;138:1095-100, discussion 1101-2. (Pubitemid 41797350)
39. de Keizer B, Koppeschaar HP, Zelissen PM, Lips CJ, van Rijk PP, van Dijk A et al. Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. Eur J Nucl Med 2001;28:198-202.
40. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996;37:598-605. (Pubitemid 126618447)
41. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306.
42. Reiners C. Radioiodine therapy in patients with pulmonary metastases of thyroid cancer: when to treat, when not to treat? Eur J Nucl Med Mol Imaging 2003;30:939-42.
43. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638-44. (Pubitemid 37464133)
44. Duntas LH, Cooper DS. Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. Thyroid 2008;18:509-16.
45. Robbins RJ, Driedger A, Magner J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 2006;16:1121-30.
46. de Keizer B, Brans B, Hoekstra A, Zelissen PM, Koppeschaar HP, Lips CJ et al. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur J Nucl Med Mol Imaging 2003;30:367-73.
47. Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 2000;85:3640-5.
48. Beierwaltes WH. The treatment of thyroid carcinoma with radioadive iodine. Semin Nucl Med 1978;8:79-94.
49. Maxon HR, III, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990;19:685-718.
50. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986;63:960-7.
51. Menzel C, Grünwald F, Schomburg A, Palmedo H, Bender H, Späth G et al. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 1996;37:1496-503.
52. Kulkarni K, Van ND, Atkins F, Aiken M, Burman K, Wartofsky L. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid 2006;16:1019-23.
53. Van Nostrand D, Atkins F, Yeganeh F, Ado E, Bursaw R, Wartofsky L. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 2002;12:121-34.
54. Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pendow K, Larson SM et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006;47:1587-91. (Pubitemid 47545022)
55. Lubberink M, Abdul FS, Brans B, Hoekstra OS, Teule GJ. The role of (124)I-PET in diagnosis and treatment of thyroid carcinoma. Q J Nucl Med Mol Imaging 2008;52:30-6. (Pubitemid 351351042)
56. 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med 2008;49:1017-23. (Pubitemid 351793444)